Korean Journal of Radiology

The Korean Society of Radiology (대한영상의학회)
권호 표지
DOI QR코드

DOI QR Code

MRI-Targeted Prostate Biopsy: What Radiologists Should Know

  • Chandan J Das (Department of Radiology, All India Institute of Medical Sciences (AIIMS)) ;
  • Arjunlokesh Netaji (Department of Radiology, All India Institute of Medical Sciences (AIIMS)) ;
  • Abdul Razik (Department of Radiology, All India Institute of Medical Sciences (AIIMS)) ;
  • Sadhna Verma (Department of Radiology, University of Cincinnati Medical Center)
  • Received : 2019.11.01
  • Accepted : 2020.03.12
  • Published : 2020.09.01
Download PDF
⟨ Previous Next ⟩

Abstract

Transrectal ultrasound (TRUS)-guided systematic biopsy, the current gold standard for the detection of prostate cancer, suffers from low sensitivity for clinically significant cancer. The use of diagnostic multiparametric MRI has increased the relevance of targeted biopsy techniques such as MRI-TRUS fusion biopsy and direct (in-bore) MRI-guided biopsy, which have higher detection rate for clinically significant cancer. Although primarily used in patients who remain at high clinical suspicion for prostate cancer despite a negative systematic biopsy, with the increasing use of upfront diagnostic MRI, these biopsies are expected to replace routine systematic biopsies. This pictorial essay aims to enhance our understanding of the concepts of these biopsy techniques so that they can be performed safely and provide maximum diagnostic yield.

Keywords

References

  1. Prostate cancer statistics. World Cancer Research Fund Web site. https://www.wcrf.org/dietandcancer/cancer-trends/prostate-cancer-statistics. Published August 22, 2018. Accesse October 8, 2019 
  2. Bonekamp D, Jacobs MA, El-Khouli R, Stoianovici D, Macura KJ. Advancements in MR imaging of the prostate: from diagnosis to interventions. Radiographics 2011;31:677-703 
  3. Schoots IG, Roobol MJ, Nieboer D, Bangma CH, Steyerberg EW, Hunink MG. Magnetic resonance imaging-targeted biopsy may enhance the diagnostic accuracy of significant prostate cancer detection compared to standard transrectal ultrasound-guided biopsy: a systematic review and meta-analysis. Eur Urol 2015;68:438-450 
  4. Ahmed HU, El-Shater Bosaily A, Brown LC, Gabe R, Kaplan R, Parmar MK, et al. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet 2017;389:815-822 
  5. Kasivisvanathan V, Rannikko AS, Borghi M, Panebianco V, Mynderse LA, Vaarala MH, et al. MRI-targeted or standard biopsy for prostate-cancer diagnosis. N Engl J Med 2018;378:1767-1777 
  6. Verma S, Choyke PL, Eberhardt SC, Oto A, Tempany CM, Turkbey B, et al. The current state of MR imaging-targeted biopsy techniques for detection of prostate cancer. Radiology 2017;285:343-356 
  7. Prostate cancer risk management programme (PCRMP): benefits and risks of PSA testing (guidance). GOV.UK Web site. https://www.gov.uk/government/publications/prostate-cancer-risk-management-programme-psa-test-benefits-and-risks/prostate-cancer-risk-management-programme-pcrmp-benefits-and-risks-of-psa-testing. Published March 29, 2016. Accessed October 8, 2019 
  8. Heidenreich A, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, et al. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol 2011;59:61-71 
  9. Fiuk JV, Holland BC, Dynda DI, Alanee SR. Antibiotics prophylaxis before prostate biopsy in practice: review of online clinical guidelines. Urol Ann 2015;7:279-280 
  10. Wegelin O, Exterkate L, van der Leest M, Kummer JA, Vreuls W, de Bruin PC, et al. The FUTURE trial: a multicenter randomised controlled trial on target biopsy techniques based on magnetic resonance imaging in the diagnosis of prostate cancer in patients with prior negative biopsies. Eur Urol 2019;75:582-590 
  11. Cool DW, Zhang X, Romagnoli C, Izawa JI, Romano WM, Fenster A. Evaluation of MRI-TRUS fusion versus cognitive registration accuracy for MRI-targeted, TRUS-guided prostate biopsy. AJR Am J Roentgenol 2015;204:83-91 
  12. Yamada Y, Shiraishi T, Ueno A, Ueda T, Fujihara A, Naitoh Y, et al. Magnetic resonance imaging-guided targeted prostate biopsy: comparison between computer-software-based fusion versus cognitive fusion technique in biopsy-naive patients. Int J Urol 2020;27:67-71 
  13. Rosenkrantz AB, Verma S, Choyke P, Eberhardt SC, Eggener SE, Gaitonde K, et al. Prostate magnetic resonance imaging and magnetic resonance imaging targeted biopsy in patients with a prior negative biopsy: a consensus statement by AUA and SAR. J Urol 2016;196:1613-1618 
  14. Das CJ, Razik A, Sharma S, Verma S. Prostate biopsy: when and how to perform. Clin Radiol 2019;74:853-864 
  15. Li M, Wang Z, Li H, Yang J, Rao K, Wang T, et al. Local anesthesia for transrectal ultrasound-guided biopsy of the prostate: a meta-analysis. Sci Rep 2017;7:40421 
  16. Gaziev G, Wadhwa K, Barrett T, Koo BC, Gallagher FA, Serrao E, et al. Defining the learning curve for multiparametric magnetic resonance imaging (MRI) of the prostate using MRI-transrectal ultrasonography (TRUS) fusion-guided transperineal prostate biopsies as a validation tool. BJU Int 2016;117:80-86 
  17. Meng X, Rosenkrantz AB, Huang R, Deng FM, Wysock JS, Bjurlin MA, et al. The institutional learning curve of magnetic resonance imaging-ultrasound fusion targeted prostate biopsy: temporal improvements in cancer detection in 4 years. J Urol 2018;200:1022-1029 
  18. Kuru TH, Herden J, Zugor V, Akbarov I, Pfister D, Porres D, et al. How to perform image-guided prostate biopsy: in-bore and fusion approaches. Eur Urol Focus 2016;2:151-153